| __timestamp | Bausch Health Companies Inc. | Viking Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2026300000 | 1244910 |
| Thursday, January 1, 2015 | 2682700000 | 5029636 |
| Friday, January 1, 2016 | 2810000000 | 4846776 |
| Sunday, January 1, 2017 | 2582000000 | 5329003 |
| Monday, January 1, 2018 | 2473000000 | 7121000 |
| Tuesday, January 1, 2019 | 2554000000 | 9128000 |
| Wednesday, January 1, 2020 | 2367000000 | 10731000 |
| Friday, January 1, 2021 | 2624000000 | 10701000 |
| Saturday, January 1, 2022 | 2625000000 | 16121000 |
| Sunday, January 1, 2023 | 2917000000 | 37021000 |
Unlocking the unknown
In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Viking Therapeutics, Inc. and Bausch Health Companies Inc. from 2014 to 2023.
Bausch Health has consistently maintained high SG&A expenses, peaking at nearly $2.9 billion in 2023, reflecting a 44% increase from 2014. This trend underscores their aggressive market presence and investment in administrative capabilities.
In contrast, Viking Therapeutics has shown a remarkable growth trajectory, with SG&A expenses surging by over 2,800% from 2014 to 2023. This indicates their strategic expansion and increased operational activities.
These trends highlight the differing strategies of these companies, with Bausch focusing on sustained market dominance and Viking on rapid growth and expansion.
Who Optimizes SG&A Costs Better? Sanofi or Viking Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Gilead Sciences, Inc. and Viking Therapeutics, Inc.
Incyte Corporation and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Catalent, Inc. vs Bausch Health Companies Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Apellis Pharmaceuticals, Inc. or Viking Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Viking Therapeutics, Inc. and CRISPR Therapeutics AG
SG&A Efficiency Analysis: Comparing Viking Therapeutics, Inc. and MorphoSys AG
Cost Management Insights: SG&A Expenses for Viking Therapeutics, Inc. and Supernus Pharmaceuticals, Inc.
Viking Therapeutics, Inc. and Mesoblast Limited: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Viking Therapeutics, Inc. vs ImmunityBio, Inc. Trends and Insights
Viking Therapeutics, Inc. and Evotec SE: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Bausch Health Companies Inc. and Taro Pharmaceutical Industries Ltd.